- The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva, Genentech) for the treatment of adults with primary membranous nephropathy (PMN) at risk of disease progression — marking the first FDA-approved therapy specifically indicated for this condition.
The approval, announced on November 13, 2026, was based on results from the Phase 3 MAJESTY trial, in which obinutuzumab demonstrated significantly higher rates of complete remission compared with the off-label standard, tacrolimus.
Primary membranous nephropathy is an autoimmune kidney disease in which antibodies — most commonly against the phospholipase A2 receptor (PLA2R) — attack the glomerular basement membrane, causing severe proteinuria and progressive kidney damage. Up to 30% of untreated patients progress to kidney failure within 10 years.
The MAJESTY trial randomized 142 adults with PMN 1:1 to intravenous obinutuzumab or oral tacrolimus for 104 weeks. Complete remission — defined as a urinary protein-to-creatinine ratio of 0.3 or lower with stable estimated glomerular filtration rate (eGFR) — was achieved in 37% of patients in the obinutuzumab group, compared with 6% in the tacrolimus group (adjusted difference: 31 percentage points; 95% CI 18–44; P < .001).
Obinutuzumab is a type II anti-CD20 monoclonal antibody that depletes CD20-positive B cells, including tissue-resident B cells implicated in the autoimmune pathogenesis of PMN. The drug had previously received FDA Breakthrough Therapy Designation for PMN in April 2026 and was placed under Priority Review.
The safety profile was consistent with known risks of obinutuzumab. Grade ≥3 adverse events occurred in 22% of patients in the obinutuzumab group versus 19% in the tacrolimus group. The prescribing information carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML).
Genentech noted that the MAJESTY data are being submitted to other health authorities, including the European Medicines Agency (EMA). The trial results were presented at the European Renal Association Congress in June 2026 and published in The New England Journal of Medicine.















